Eytan M. Stein, MD – Hematologist-Oncologist – Memorial Sloan Kettering Cancer Center
Discover the cutting-edge landscape of acute myeloid leukemia (AML) treatment with a focus on Revumenib and Ziftomenib, two promising menin inhibitors. Delving into the realm of AML therapy, this discussion navigates through the potential roles of Revumenib and Ziftomenib in treating relapsed and refractory cases, particularly among patients with KMT2A rearrangements and NPM1 mutations.
The presentation sheds light on the intricate binding properties and resistance patterns of these inhibitors, unraveling the nuances that dictate their efficacy. As the journey unfolds, Eytan M. Stein, MD underscores the need for rigorous research to optimize these agents, addressing issues of tolerability, resistance mutation emergence, and the aspiration to extend their application beyond the horizon of genetic mutations. With a fervent focus on the innovative potential of Revumenib and Ziftomenib, this discourse illuminates the trajectory of AML treatment, paving the way for targeted therapy advancements.